JP2016528174A5 - - Google Patents

Download PDF

Info

Publication number
JP2016528174A5
JP2016528174A5 JP2016517040A JP2016517040A JP2016528174A5 JP 2016528174 A5 JP2016528174 A5 JP 2016528174A5 JP 2016517040 A JP2016517040 A JP 2016517040A JP 2016517040 A JP2016517040 A JP 2016517040A JP 2016528174 A5 JP2016528174 A5 JP 2016528174A5
Authority
JP
Japan
Prior art keywords
item
cdp
conjugate
jak inhibitor
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016517040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/040230 external-priority patent/WO2014194195A2/en
Publication of JP2016528174A publication Critical patent/JP2016528174A/ja
Publication of JP2016528174A5 publication Critical patent/JP2016528174A5/ja
Pending legal-status Critical Current

Links

JP2016517040A 2013-05-31 2014-05-30 治療的送達用のシクロデキストリンベースのポリマー Pending JP2016528174A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829797P 2013-05-31 2013-05-31
US61/829,797 2013-05-31
PCT/US2014/040230 WO2014194195A2 (en) 2013-05-31 2014-05-30 Cyclodextrin-based polymers for the therapeutic delivery

Publications (2)

Publication Number Publication Date
JP2016528174A JP2016528174A (ja) 2016-09-15
JP2016528174A5 true JP2016528174A5 (enExample) 2017-07-13

Family

ID=51985801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517040A Pending JP2016528174A (ja) 2013-05-31 2014-05-30 治療的送達用のシクロデキストリンベースのポリマー

Country Status (5)

Country Link
US (2) US20140357557A1 (enExample)
JP (1) JP2016528174A (enExample)
AU (1) AU2014273983A1 (enExample)
CA (1) CA2913752A1 (enExample)
WO (1) WO2014194195A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013814B2 (en) * 2017-03-16 2021-05-25 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
CN105924444B (zh) * 2015-03-11 2019-06-18 苏州晶云药物科技股份有限公司 Jak抑制剂的晶型及其制备方法
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
US20180318306A1 (en) * 2015-09-28 2018-11-08 Cti Biopharma Corp. Methods of treating transplant rejection
CA3000951A1 (en) * 2015-10-20 2017-04-27 Emory University Response-guided hcv therapy
AU2016359494B2 (en) * 2015-11-24 2021-01-07 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
WO2017177055A1 (en) * 2016-04-08 2017-10-12 Liang Zhao Cyclodextrin-based polymers for therapeutic delivery
AU2017378398B2 (en) * 2016-12-14 2023-02-02 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
US10472366B2 (en) 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
US10233174B2 (en) 2017-05-23 2019-03-19 Theravance Biopharma R&D Ip, Llc Thiocarbamate prodrugs of tofacitinib
BR112019024509A2 (pt) 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
US11666654B2 (en) 2017-11-03 2023-06-06 Sdg Llc Drug delivery system for treating disease
JP6670982B2 (ja) * 2018-03-30 2020-03-25 生化学工業株式会社 生物活性を有するカルボン酸型化合物−ポリマーコンジュゲート及びその製造方法
US10912759B2 (en) * 2018-05-17 2021-02-09 William Andrew Clark Topical gel compositions for the treatment of Staphylococcal infections
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110403944A (zh) * 2019-08-07 2019-11-05 中南大学湘雅医院 Decernotinib在制备治疗银屑病的外用药物中的应用、药物及制备方法
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
IL309840A (en) * 2021-07-20 2024-02-01 Coval Biopharma Shanghai Co Ltd An external antidialectic coupling compound drug, and a method of preparation therefor and use thereof
WO2023039213A1 (en) * 2021-09-09 2023-03-16 Biora Therapeutics, Inc. Aqueous formulations of tofacitinib and tofacitinib salts
KR20240150493A (ko) * 2022-02-21 2024-10-15 온퀄리티 파마슈티컬스 차이나 리미티드 화합물 및 그 용도
EP4536234A1 (en) * 2022-06-13 2025-04-16 Emory University Uses of jak inhibitors in the management of inflammation-associated depression and central nervous system (cns) pathologies
WO2025040148A1 (zh) * 2023-08-22 2025-02-27 北京普祺医药科技股份有限公司 一种用于jak抑制剂的外用凝胶及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098611A1 (en) * 2006-03-03 2007-09-07 Queen's University At Kingston Compositions for treatment of cancer
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US9351943B2 (en) * 2010-07-01 2016-05-31 Matthew T. McLeay Anti-fibroblastic fluorochemical emulsion therapies
WO2012044832A1 (en) * 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors

Similar Documents

Publication Publication Date Title
JP2016528174A5 (enExample)
Birke et al. Polypeptoid-block-polypeptide copolymers: Synthesis, characterization, and application of amphiphilic block copolypept (o) ides in drug formulations and miniemulsion techniques
CN101541347B (zh) 药物载体、其合成及其使用方法
Moore et al. Multifunctional polymer‐coated carbon nanotubes for safe drug delivery
ES2525257T3 (es) Composiciones de ciclopolisacárido y de bendamustina
JP2016153410A5 (enExample)
JP2015528002A5 (enExample)
JP2014531476A5 (enExample)
JP2017505104A5 (enExample)
JP2011523643A5 (enExample)
JP2011530597A5 (enExample)
JP2019512478A5 (enExample)
JP2018510863A5 (enExample)
JP2019512006A5 (enExample)
JP2019523761A5 (enExample)
JP2001514167A5 (enExample)
JP2010513441A5 (enExample)
US20220054659A1 (en) Psma-targeted pamam dendrimers for specific delivery of imaging, contrast and therapeutic agents
CN108601952B (zh) 雷公藤内酯的葡萄糖缀合物、类似物及其用途
CN102174579B (zh) 可还原降解的梳型高分子基因载体及其制备方法
JP2009536246A5 (enExample)
RU2020126774A (ru) Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения
RU2018128032A (ru) Полимеры на основе циклодекстрина, способы, композиции и применение
JP2016511777A5 (enExample)
JP2011506296A5 (enExample)